Head to Head Review: Ridgepost Capital (NYSE:RPC) & BR Biopharma (NASDAQ:BRBI)

Ridgepost Capital (NYSE:RPC) and BR Biopharma (NASDAQ:BRBI) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Dividends

Ridgepost Capital pays an annual dividend of $0.16 per share and has a dividend yield of 1.9%. BR Biopharma pays an annual dividend of $0.51 per share and has a dividend yield of 5.5%. Ridgepost Capital pays out 64.0% of its earnings in the form of a dividend.

Insider & Institutional Ownership

48.0% of Ridgepost Capital shares are owned by institutional investors. 11.8% of Ridgepost Capital shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ridgepost Capital and BR Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ridgepost Capital	$297.35 million	3.12	$19.50 million	$0.25	33.67
BR Biopharma	$2.23 billion	0.05	$31.36 million	N/A	N/A

BR Biopharma has higher revenue and earnings than Ridgepost Capital.

Profitability

This table compares Ridgepost Capital and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ridgepost Capital	9.03%	21.02%	9.21%
BR Biopharma	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ridgepost Capital and BR Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ridgepost Capital	0	2	2	0	2.50
BR Biopharma	1	0	0	0	1.00

Ridgepost Capital presently has a consensus price target of $11.00, suggesting a potential upside of 30.69%. Given Ridgepost Capital’s stronger consensus rating and higher possible upside, research analysts plainly believe Ridgepost Capital is more favorable than BR Biopharma.

Summary

Ridgepost Capital beats BR Biopharma on 9 of the 13 factors compared between the two stocks.

About Ridgepost Capital

P10, Inc., together with its subsidiaries, operates as a multi-asset class private market solutions provider in the alternative asset management industry in the United States. The company offers private equity, venture capital, private credit, impact investing, and private credit services, as well as primary fund of funds, secondary investment, and direct and co-investments services. It also provides tax credit transaction and consulting services. The company was founded in 1992 and is headquartered in Dallas, Texas.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.